nach oben

Nuclear Medicine and Molecular Imaging

Erschienen in:

17.05.2021 | Editorial

Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements

verfasst von: Andrew M. Scott

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Excerpt

Nuclear medicine in Korea has been an exemplar of the changes in our profession with time, and the impact our speciality can have on the treatment of patients. The editorial article “Short Essay on 60 years’ Challenges and Achievements of KSNM,” by Drs. HG Ryoo, M Suh, JC Paeng, and JK Chung provides an important history of the development and achievements of the nuclear medicine community in Korea [1]. The accomplishments are remarkable, and Korea truly sits with the major international countries for clinical implementation, academic achievements, and professional leadership at a country, regional, and international level. …

Ryoo HG, Suh M, Paeng JC, Chung J-K. Short essay on 60 years’ challenges and achievements of KSNM. Nucl Med Mol Imag. 2021;55:2–6.CrossRef

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.CrossRef

FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer. Accessed 4 Apr 2021.

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. 177Lu-PSMA-617 versus cabazitaxel in metastatic castration resistant prostate cancer. Lancet. 2021;397:797–804. https://doi.org/10.1016/S0140-6736(21)00237-3.CrossRefPubMed

Phase 3 trial of 177Lu-PSMA-617 meets survival end points. https://www.cancernetwork.com/view/phase-3-trial-of-177lu-psma-617-meets-survival-end-points. Accessed 4 Apr 2021.

Francis RJ, Bailey DL, Hofman MS, Scott AM. The Australasian Radiopharmaceutical Trials Network (ARTnet) – clinical trials, evidence and opportunity. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.258152.CrossRefPubMed

Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, et al. Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol. 2021;22:e136–72.CrossRef

Cutler CS, Bailey E, Kumar V, Schwarz SW, Bom HS, Hatazawa J, et al. Global issues of radiopharmaceutical access and availability: a nuclear medicine global initiative project. J Nucl Med. 2021;62:422–30.CrossRef

Titel: Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements
verfasst von: Andrew M. Scott
Publikationsdatum: 17.05.2021
Verlag: Springer Singapore
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 4/2021
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-021-00700-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers

Incidental Detection of Ischemic Myocardium on 68 Ga-FAPI PET/CT

Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68 Ga-PSMA PET/CT vs mpMRI

The Role of Tc-99 m-MIBI Scan in the Assessment of the Cystic Thyroid Nodule

KSNM60 in Cardiology: Regrowth After a Long Pause

18F-FDG PET/CT Evaluation of Thymomas: a Pictorial Review